Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 628 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Non-communicable Disease Clear all

Conditions: HIV Infections
Interventions: Lamivudine, Zidovudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 12 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 18
States / cities: Los Angeles, California • San Diego, California • Sherman Oaks, California + 15 more

Conditions: HIV Infections, Hiv, Sexually Transmitted Infections (Not HIV or Hepatitis), Sexually Transmitted Diseases, Sexual Behavior, Risk Reduction
Interventions: Para ti, para mi, para nosotros (P3), Waitlist Control Para ti, para mi, para nosotros (P3); Behavioral
Lead sponsor: Florida International University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 148 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV Infections
Interventions: Indinavir sulfate, Ritonavir, Stavudine, Didanosine; Drug
Lead sponsor: PPD Development, LP; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 13
States / cities: Berkeley, California • Los Angeles, California • Fort Lauderdale, Florida + 8 more

Conditions: Hepatitis C Virus, Liver Transplantation
Interventions: Not listed
Lead sponsor: Schiano, Thomas D., MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C, Hepatitis C, Chronic
Interventions: thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a, placebo + PEGinterferon alfa-2a; Drug
Lead sponsor: SciClone Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 46
States / cities: Mobile, Alabama • Scottsdale, Arizona • Berkeley, California + 36 more

Conditions: Chronic Hepatitis C, Genotype 1, Relapse
Interventions: Betaine, Peginterferon alpha 2a, Ribavirin; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: HIV Infection
Interventions: efavirenz, tenofovir, abacavir/lamivudine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 58
States / cities: Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 42 more

Conditions: Hepatitis C
Interventions: Peg-Intron, REBETOL, HCV 796; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 34
States / cities: Anaheim, California • La Jolla, California • Los Angeles, California + 26 more

Conditions: Lung Cancer
Interventions: carboplatin, gemcitabine hydrochloride, paclitaxel; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Clostridium Difficile, Clostridium Difficile Infection, Microbiome, CDI
Interventions: No Intervention; Other
Lead sponsor: ProgenaBiome; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Ventura, California

Conditions: Hepatitis C Virus Infection
Interventions: VOX, SOF/VEL; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 31
States / cities: Los Angeles, California • Palo Alto, California • Pasadena, California + 26 more

Conditions: Non-infectious Uveitis
Interventions: AIN457, Placebo; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 24
States / cities: Artesia, California • Beverly Hills, California • Atlanta, Georgia + 10 more

Conditions: Covid19, SARS-CoV Infection
Interventions: Not listed
Lead sponsor: Jill M Kolesar; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: HIV Infections
Interventions: Emtricitabine, Lamivudine; Drug
Lead sponsor: Triangle Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: St. Petersburg, Florida • Great Neck, New York

Conditions: Uveitis
Interventions: ACTH gel; Drug
Lead sponsor: Quan Dong Nguyen; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 7
States / cities: Los Angeles, California • Palo Alto, California • Waltham, Massachusetts + 3 more

Conditions: Complication of Transplanted Liver, Hepatitis C, Chronic
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Covid19
Interventions: Atovaquone/Azithromycin; Drug
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years to 95 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: NAFLD, NAFLD-HIV, Hiv
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 1,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 8
States / cities: Tuscaloosa, Alabama • La Jolla, California • San Francisco, California + 5 more

Conditions: Non-infectious Uveitis
Interventions: AIN457, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 10
States / cities: Beverly Hills, California • Atlanta, Georgia • Louisville, Kentucky + 7 more

Conditions: Meningitis, Cryptococcal, HIV Infections
Interventions: Fluconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 5
States / cities: Oakland, California • Chicago, Illinois • Brooklyn, New York + 2 more

Conditions: Surgical Site Infection, Antibiotic Prophylaxis
Interventions: Antibiotics; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cancer
Interventions: itraconazole, voriconazole; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 12 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cancer
Interventions: infection prophylaxis and management; Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 12 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2002
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions: Lactobacillus rhamnosus GG; Dietary Supplement
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 120 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Search by objective public record fields.

A Comparison of Lamivudine and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Not Used Zidovudine in the Past

Acceptability, Feasibility, and Preliminary Impact of a Web-based, HIV Prevention Toolkit With Cisgender Male Couples in Lima, Peru

Differences Between Women and Men Taking a Combination of Indinavir, Ritonavir, Enteric-Coated Didanosine, and Stavudine Who Previously Took Anti-HIV Drugs

Assessment of Intrahepatic Hepatitis C Virus (HCV) RNA Levels at the Time of Liver Transplantation

Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin

Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers

A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy

A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects

Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Clostridoides Difficile Infection

Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

A Registry Study of COVID-19 Serologic and Virologic Testing to Accelerate Recovery and Transition

Comparing FTC and Lamivudine in HIV-Infected Patients on a Stable Anti-HIV Drug Combination

ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study)

Prediction of Hepatitis C Recurrence in Liver Transplant Recipients

Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection

Prevalence and Predictors of Hepatic Steatosis in Persons Living With HIV

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis

The Role of Guideline-adherent Perioperative Antibiotic Administration and the Risk of Surgical Site Infections After Non-cardiac Surgery.

Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation

Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome